At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective International Multicenter Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Mexidol® in Sequential Treatment of Patients in the Acute and Early Recovery Periods of Ischemic Stroke
In Brief
A Phase 3 clinical trial evaluating Mexidol (Ethylmethylhydroxypyridine Succinate) and Placebo for Ischemic Stroke. Completed, enrolled 304 participants across 17 sites in 3 countries.
Detailed Summary
The main purpose of the clinical trial is to evaluate the efficacy and safety of Mexidol® in sequential treatment for patients in the acute and early recovery periods of ischemic stroke compared to placebo. The effect of adding Mexidol® to standard therapy on the degree of impairment of vital functions was assessed including the degree of disability (according to the Modified Rankin Scale, mRS), the severity of neurological symptoms (according to the National Institutes of Health Stroke Scale, NIHSS) and the level of mobility of patients (according to the Rivermead Mobility Index).
Study Details
Timeline
Interventions
50 mg/ml IV solution, 250 mg tablets
Placebo IV solution, Placebo tablets